InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

InflaRx N.V.NASDAQ: IFRX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of €87.18K fell 23.4% year over year, behind the -17.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.1% from the prior quarter. Over 3 fiscal years it compounded at -11.1% a year.

Context

  • Depreciation & amortization amounted to 1430.2% of revenue in FY2025, up 1137.6 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -23.4% toward the trailing-twelve-month pace of -17.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€87.18K-4.1% QoQ
Last fiscal yearDec 2025
€419.48K-13.5% YoY
LTMMar 2026
€392.86K-17.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.4%——
1 year-13.5%——
3-year CAGR-11.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the income statement

Latest · FY2025
419.48K EUR
Year-over-year change
-13.5%
4-year CAGR
-11.0%

Depreciation & Amortization vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.3% is the lowest of 8, against a peer median of +6.6%.
  • Depreciation & amortization amounts to 1339.4% of revenue for IFRX, versus a peer median of 534.8%.
IFRX Competitors
Depreciation & Amortization for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M USD-8.9%-4.0%6.7%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.64M USD+6.6%+30.9%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$1.34M USD+0.8%-2.9%705.3%
IMAImageneBio IncLTM Mar 2026$822K USD+129.6%+11.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.9%1100.0%
IFRXInflaRx N.V.LTM Mar 2026€392.86K EUR-17.3%-11.1%1339.4%
CNTXContext Therapeutics Inc.LTM Mar 2026$48.3K USD+290.5%+20.6%—
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
Peer median (excluding IFRX) —+6.6%+6.3%534.8%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0063.09K165.79K29.33K
Cost of Revenue00532.26K3.32M7.27M
Gross Profit00(469.17K)(3.15M)(7.24M)
Gross Margin——-743.7%-1900.8%-24677.9%
Research & Development35.7M37.53M41.02M35.36M25.72M
Selling, General & Admin11.43M14.34M16.12M19.33M17.56M
Operating Expenses47.63M32.24M44.13M49.75M41.02M
Depreciation & Amortization669.43K596.6K567.78K485.11K419.48K
EBITDA(44.94M)(28.84M)(42.06M)(45.55M)(45.16M)
EBITDA Margin——-66674.3%-27476.7%-153976.3%
Operating Income(47.63M)(32.24M)(44.59M)(52.91M)(48.26M)
Operating Margin——-70685.6%-31911.4%-164525.5%
Interest Income109.39K608.68K3.8M3.2M1.77M
Interest Expense24.77K45.25K35.63K20.66K37.69K
Other Income / Expenses2M2.75M1.93M6.85M2.64M
Income Before Tax(45.63M)(29.48M)(42.67M)(46.06M)(45.62M)
Pre-Tax Margin——-67630.7%-27781.8%-155540.2%
Income Tax Expense0005.22K12.28K
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(45.63M)
Net Margin——-67630.7%-27785.0%-155582.1%
EPS (Basic)(1.10)(0.61)(0.78)(0.78)(0.66)
EPS (Diluted)(1.10)(0.61)(0.78)(0.78)(0.66)
Weighted Avg Shares41.63M44.21M54.94M58.92M67.29M
Weighted Avg Shares (Diluted)41.63M44.21M54.94M58.92M67.29M

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.